Camidanlumab tesirine - ADC Therapeutics

Drug Profile

Camidanlumab tesirine - ADC Therapeutics

Alternative Names: ADCT-301; HuMax®-TAC-ADC

Latest Information Update: 21 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADC Therapeutics; Genmab
  • Developer ADC Therapeutics
  • Class Antineoplastics; Benzodiazepines; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 20 Aug 2018 Camidanlumab tesirine is still in phase I development for Hodgkin lymphoma and Non-Hodgkin Lymphoma in United Kingdom and USA (NCT02432235)
  • 20 Aug 2018 ADC Therapeutics plans a phase I trial for Solid tumours (Late-stage disease) in USA (IV, infusion) (NCT03621982)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Hodgkin's-disease(Second-line therapy or greater) in United Kingdom (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top